Business Description
Xbrane Biopharma AB
ISIN : SE0007789409
Compare
Compare
Traded in other countries / regions
XBRANE.Sweden7XB.GermanyXBRANs.UK IPO Date
2020-07-21Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.17 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.59 | |||||
Debt-to-EBITDA | -0.7 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.22 | |||||
Beneish M-Score | -0.66 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 177.8 | |||||
3-Year EBITDA Growth Rate | 3.2 | |||||
3-Year EPS without NRI Growth Rate | 3.5 | |||||
3-Year FCF Growth Rate | -3.3 | |||||
3-Year Book Growth Rate | -20.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.24 | |||||
9-Day RSI | 43.91 | |||||
14-Day RSI | 45.82 | |||||
6-1 Month Momentum % | -83.46 | |||||
12-1 Month Momentum % | -98.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.93 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 0.73 | |||||
Days Inventory | 260.54 | |||||
Days Sales Outstanding | 2.2 | |||||
Days Payable | 86.17 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10.3 | |||||
Shareholder Yield % | -153.01 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 15.42 | |||||
Operating Margin % | -176.82 | |||||
Net Margin % | -223.59 | |||||
FCF Margin % | -242.78 | |||||
ROE % | -128.35 | |||||
ROA % | -52.19 | |||||
ROIC % | -57.01 | |||||
ROC (Joel Greenblatt) % | -400.05 | |||||
ROCE % | -70.84 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.38 | |||||
PB Ratio | 1.08 | |||||
Price-to-Tangible-Book | 1.96 | |||||
EV-to-EBIT | -1.17 | |||||
EV-to-Forward-EBIT | -1.47 | |||||
EV-to-EBITDA | -1.17 | |||||
EV-to-Forward-EBITDA | -1.47 | |||||
EV-to-Revenue | 2.03 | |||||
EV-to-Forward-Revenue | 1.23 | |||||
EV-to-FCF | -0.84 | |||||
Price-to-Net-Current-Asset-Value | 1.96 | |||||
Earnings Yield (Greenblatt) % | -85.47 | |||||
FCF Yield % | -108.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xbrane Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 16.59 | ||
EPS (TTM) (€) | -0.14 | ||
Beta | 1.18 | ||
Volatility % | 195.63 | ||
14-Day RSI | 45.82 | ||
14-Day ATR (€) | 0.002818 | ||
20-Day SMA (€) | 0.022445 | ||
12-1 Month Momentum % | -98.16 | ||
52-Week Range (€) | 0.012509 - 0.9026 | ||
Shares Outstanding (Mil) | 1,529.48 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xbrane Biopharma AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xbrane Biopharma AB Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Xbrane Biopharma AB Frequently Asked Questions
What is Xbrane Biopharma AB(STU:7XB)'s stock price today?
The current price of STU:7XB is €0.02. The 52 week high of STU:7XB is €0.90 and 52 week low is €0.01.
When is next earnings date of Xbrane Biopharma AB(STU:7XB)?
The next earnings date of Xbrane Biopharma AB(STU:7XB) is 2024-07-17.
Does Xbrane Biopharma AB(STU:7XB) pay dividends? If so, how much?
Xbrane Biopharma AB(STU:7XB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |